CONNECT WITH US
HealthTech

HealthTech

Imaging-based modalities compared for identifying at-risk MASH

Medical Xpress logo

Published on

Add as a preferred source on Google
Imaging-based modalities compared for identifying at-risk MASH

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

FibroScan-aspartate aminotransferase (FAST) demonstrated the highest sensitivity for ruling out at-risk metabolic dysfunction-associated steatohepatitis (MASH), according to a study published in the October issue of the American Journal of Gastroenterology.

Shyna Zhuoying Gunalan, from the National University of Singapore, and colleagues conducted a systematic review to identify studies reporting on magnetic resonance imaging (MRI)-based diagnostic techniques for at-risk MASH. The diagnostic performance of imaging-based technologies for ruling in (TRI) and ruling out (TRO) at-risk MASH was evaluated. Twenty studies, with 9,480 participants, met the inclusion criteria.

The researchers found that FAST demonstrated the highest TRO sensitivity, with moderate specificity (0.871 and 0.567, respectively); TRI specificity and sensitivity were 0.900 and 0.441, respectively. High TRO sensitivity was achieved with magnetic resonance elastography plus fibrosis-4, while specificity was lower (0.812 and 0.606, respectively); specificity and sensitivity for TRI were 0.872 and 0.500, respectively. Intermediate performance was achieved with MRI-aspartate aminotransferase, while variable diagnostic accuracy was seen for iron-corrected T1 mapping thresholds. Compared with other diagnostic methods, superior performance was seen in FAST in a sensitivity analysis of head-to-head studies.

"Given the findings, the FAST score may be the most practical option for wide-scale implementation, offering ease of access and a relatively lower cost compared with other diagnostic methods," the authors write. "However, magnetic resonance-based technologies also provide strong evidence for the identification of at-risk MASH."


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.